Market Research Report

U.S. BREAST DISEASE DIAGNOSIS AND THERAPY MARKETS
cover Published by Life Science Intelligence, Inc.
Published Product code 74175
Content info 244 Pages / 98 Exhibits
Price

Introduction

Abstract

Overview

The breast disease diagnosis and therapy markets are poised for substantial and sustainable growth, according to this new report from Life Science Intelligence (LSI). The report, Breast Disease Diagnosis and Therapy Markets, 2007, finds that the $550 million U.S. digital mammography segment is expected to grow more than 50% annually during the next 3 years as digital technology replaces analog. In addition, the $167 million US vacuum-assisted biopsy segment will also experience dramatic growth reaching over $350 million in the U.S. by 2012. This in-depth report provides a deep and discrete analysis of the patients, procedures, technologies and companies driving growth and innovation in the U.S. markets for breast disease diagnosis and therapy.

Coverage includes:

  • Non-Interventional Breast Disease Diagnosis - Mammography, computer-aided diagnosis, magnetic resonance imaging, diagnostic ultrasound, screening ultrasound, and various other diagnostic methods.
  • Interventional Breast Disease Diagnosis - Ultrasound-guided breast biopsy, stereotactic-guided breast biopsy, spring-loaded and vacuum-assisted biopsy techniques, and other methods.
  • Breast Disease Therapy - Treatment of benign breast disease including surgical intervention, cryoablation, thermoablation, and percutaneous excision. Treatment of malignant breast disease including surgical excision and breast brachytherapy.

    Table of Contents

    Table of Contents

    1. EXECUTIVE SUMMARY

    • 1.1 Methodology
    • 1.2 Disease Incidence
    • 1.3 Non-Interventional Diagnosis
      • 1.3.1 Screening and Diagnostic Mammography
      • 1.3.2 Screening and Diagnostic Ultrasound
      • 1.3.3 Magnetic Resonance Imaging
      • 1.3.4 Other Non-Interventional Modalities
    • 1.4 Interventional Diagnosis
    • 1.5 Breast Therapies and Therapeutic Devices
    • Exhibit 1.1: Incidence of Breast Cancer (2006-2012E)
    • Exhibit 1.3: Incidence of Benign Fibroadenomas (2006-2012E)
    • Exhibit 1.4: Non-Interventional Breast Diagnostic System and Service Sales, Market Forecast (2006-2012E)
    • Exhibit 1.5: Screening Mammograms, Procedure Forecast (2006-2012E)
    • Exhibit 1.6: Full-Field Digital Mammography System Sales, Market Forecast (2006-2012E)
    • Exhibit 1.7: Full-Field Digital Mammography System Sales, Share by Supplier (2006)
    • Exhibit 1.8: Breast Ultrasound Market Forecast (2006-2012E)
    • Exhibit 1.9: Breast Ultrasound Market, Share by Supplier (2006)
    • Exhibit 1.10: Breast MRI Market Forecast (2006-2012E)
    • Exhibit 1.11: Breast MRI Market, Share by Supplier (2006)
    • Exhibit 1.12: Interventional Breast Diagnostic Disposable and Capital Equipment Sales, Market Forecast (2006-2012E)
    • Exhibit 1.13: Breast Biopsy Procedure Forecast, by Guidance Method (2006-2012E)
    • Exhibit 1.14: Breast Biopsy Devices Market Forecast (2006-2012E)
    • Exhibit 1.15: Spring-Loaded Biopsy Device Sales, Share by Supplier (2006)
    • Exhibit 1.16: Vacuum-Assisted Biopsy Device Sales, Share by Supplier (2006)
    • Exhibit 1.17: Biopsy Marker Device Market Forecast (2006-2012E)
    • Exhibit 1.18: Biopsy Marker Device Market, Share by Supplier (2006)
    • Exhibit 1.19: Excision Procedure Volume Forecast (2006-2012E)
    • Exhibit 1.20: Lumpectomy Procedure Volume Forecast (2006-2012E)
    • Exhibit 1.21: Breast Brachytherapy Market Forecast (2006-2012E)
    • Exhibit 1.22: Total Breast Healthcare Market Forecast, by Service Type (2006-2012E)
    • Exhibit 1.23: Total Breast Healthcare Market, by Service Type, (2006)
    • Exhibit 1.24: Total Breast Healthcare Market, Share by Supplier (2006)

    2. Breast Disease Clinical Background and Statistics

    • 2.1 Breast Anatomy
    • 2.2 Malignant Breast Disease
      • 2.2.1 Invasive Breast Cancer
      • 2.2.2 Ductal Carcinoma in-situ
      • 2.2.3 Atypical Ductal Hyperplasia / Atypical Lobular Hyperplasia
      • 2.2.4 Tumor Staging
    • 2.3 Risk Factors: Breast Cancer
    • 2.4 Disease Prevalence and Forecasts
    • 2.5 Benign Breast Disease
      • 2.5.1 Fibroadenoma
      • 2.5.2 Cyst
      • 2.5.3 Fibrocystic Disease
      • 2.5.4 Benign Papilloma
    • 2.6 Summary and Conclusions
    • Exhibit 2.1: Breast Anatomy and Malignant Disease States
    • Exhibit 2.2: Inconsistency in DCIS / ADH Diagnosis
    • Exhibit 2.3: Breast Cancer Staging and Survivability
    • Exhibit 2.4: Breast Cancer Staging and Treatment Options
    • Exhibit 2.5: US Population Trends
    • Exhibit 2.6: Breast Cancer Diagnosis and Mortality: Historical Trends and Forecasts
    • Exhibit 2.7: Breast Cancer Staging and Survivability
    • Exhibit 2.8: Worldwide Distribution of Breast Cancer
    • Exhibit 2.9: Benign Fibroadenoma Diagnoses Forecasts (2006-2012E)

    3. Non-Interventional Breast Disease Diagnosis

    • 3.1 Screening and Diagnostic Mammography
      • 3.1.1 Mammography Process
        • 3.1.1.1 Acquisition
        • 3.1.1.2 Review
        • 3.1.1.3 Diagnostic Exam
        • 3.1.1.4 Dedicated Mammography Center
      • 3.1.2 Reimbursement
      • 3.1.3 Product Offerings
        • 3.1.3.1 Image Acquisition Systems
          • 3.1.3.1.1 Direct Capture vs. Indirect Capture
          • 3.1.3.1.2 Resolution
          • 3.1.3.1.3 Cost
        • 3.1.3.2 Market Analysis (Including Drivers, Limiters, and Opportunities)
      • 3.1.4 Digital Mammography Workstations
        • 3.1.4.1 Market Analysis (Including Drivers, Limiters, and Opportunities)
      • 3.1.5 Digitizers
    • 3.2 Computer Aided Diagnostics
      • 3.2.1 Background
      • 3.2.2 Market Analysis (Including Drivers, Limiters, and Opportunities)
    • 3.3 Diagnostic Ultrasound
      • 3.3.1 Ultrasound Technology
      • 3.3.2 Diagnostic Ultrasound Procedure
      • 3.3.3 Market Analysis (Including Drivers, Limiters, and Opportunities)
        • 3.3.3.1 Non-Breast Dedicated Radiology
        • 3.3.3.2 Breast Dedicated Radiology
        • 3.3.3.3 Surgeons
    • 3.4 Screening Ultrasound
      • 3.4.1 Technologies
        • 3.4.1.1 Ultrasound computed tomography (CT)
        • 3.4.1.2 Robotic Scanning
        • 3.4.1.3 Cine Approach
      • 3.4.2 Market Analysis (Including Drivers, Limiters, and Opportunities)
    • 3.5 Magnetic Resonance Imaging (MRI)
      • 3.5.1 Technology Overview
      • 3.5.2 Market Analysis (Including Drivers, Limiters, and Opportunities)
    • 3.6 Other Diagnostic Methods:
      • 3.6.1 Angiogenesis Monitors
    • 3.7 PACS
    • 3.8 S Summary and Conclusions
      • 3.8.1 Screening and Diagnostic Mammography
      • 3.8.2 Screening and Diagnostic Ultrasound
      • 3.8.3 Magnetic Resonance Imaging
      • 3.8.4 Other Non-Interventional Modalities
    • Exhibit 3.1: Mammography
    • Exhibit 3.2: Mammographic Resolution
    • Exhibit 3.3: 2007 Medicare Reimbursement, Mammography
    • Exhibit 3.4: Economic Efficiency of Mammography Program, Effect of Personnel Efficiency
    • Exhibit 3.5: Economic Efficiency of Mammography Program, Effect of Digital versus Analog Technologies
    • Exhibit 3.6: Screening Mammogram Procedure Volumes, Historical (1991-2005)
    • Exhibit 3.7: Screening Mammogram Procedure Volume Forecast (2006-2012E)
    • Exhibit 3.8: Screening and Diagnostic Flowchart and Procedure Statistics
    • Exhibit 3.9: Reduction in Tumor Size at Diagnosis: Response to Screening Mammography Program
    • Exhibit 3.10: Changes in Cancer Staging at Diagnosis: Response to Screening Mammography Program
    • Exhibit 3.11: Distribution and Analysis of Mammography Centers in US
    • Exhibit 3.12: Full-Field versus Analog Mammography System: Installed Base (2003-2012E)
    • Exhibit 3.13: Full-Field Digital Mammography Systems: Detector Types
    • Exhibit 3.14: Full-Field Digital vs. Analog Mammography Systems: Image Quality
    • Exhibit 3.15: Full-Field Digital Mammography System Market Forecast (2006-2012E)
    • Exhibit 3.16: Full-Field Digital Mammography System Market, Units, by Supplier (2006)
    • Exhibit 3.16: Full-Field Digital Mammography System Market, Share by Supplier (2006)
    • Exhibit 3.19: Digital Mammography Workstations or Breast-Specific PACS Sales Forecast (2006-2012E)
    • Exhibit 3.20: Digital Mammography Workstations Market, Share by Supplier (2006)
    • Exhibit 3.21: Breast Computer Aided Detection Market Analysis and Forecast: Successful Implementation of a Pay-Per-View Model
    • Exhibit 3.22: Breast Computer Aided Detection Market, Share by Supplier (2006)
    • Exhibit 3.23: Breast Ultrasound Images
    • Exhibit 3.24: Breast Ultrasound Market Analysis: Installed Units and Procedure Volumes
    • Exhibit 3.25: Breast Ultrasound Market: System Sales Forecast (2006-2012E)
    • Exhibit 3.26: Effectiveness of Various Diagnostic Techniques
    • Exhibit 3.27: Breast Ultrasound Market, Share as a Percentage of Total Medical Ultrasound Market (2006)
    • Exhibit 3.28: Breast Ultrasound Market, Share by Supplier( 2006)
    • Exhibit 3.29: Screening Breast Ultrasound Technologies
    • Exhibit 3.30: Screening Breast Ultrasound Market Forecast: Patient-Pay, Rapid Adoption Scenario
    • Exhibit 3.31: Breast Mammography versus Breast MRI
    • Exhibit 3.32: Breast MRI: Number of Centers and Device Utilization (2007, 2012E)
    • Exhibit 3.33: Breast MRI Market Forecast, Units (2006-2012E)
    • Exhibit 3.34: Breast MRI Market Forecast, Revenue (2006-2012E)
    • Exhibit 3.35: Breast MRI Market, Share by Supplier (2006)
    • Exhibit 3.36: Non-Interventional Breast Diagnostic System Sales Forecast (2006-2012E)
    • Exhibit 3.37: Non-Interventional Breast Diagnostic System and Service Sales (2006-2012E)
    • Exhibit 3.38: Non-Interventional Breast Diagnostic System and Service Sales, Share by Supplier (2006)

    4. Interventional Breast Disease Diagnosis

    • 4.1 Histopathology
    • 4.2 Breast Specific Antigens
    • 4.3 Ductal Lavage
    • 4.4 Biopsy Methods
      • 4.4.1 Guidance Methods
      • 4.4.2 Fine Needle Aspiration
      • 4.4.3 Spring-Loaded Core Needle Biopsy:
      • 4.4.4 Vacuum-Assisted Core Needle Biopsy
      • 4.4.5 Large-Volume Contiguous Biopsy Devices
      • 4.4.6 Biopsy Marking Devices
    • 4.5 Reimbursement Considerations
    • 4.6 Procedure Forecasts
      • 4.6.1 Surgical Excision
      • 4.6.2 Fine Needle Aspiration
      • 4.6.3 Spring-Loaded Core Needle Devices:
      • 4.6.4 Vacuum-Assisted Core Needle Devices
      • 4.6.5 Large Volume / Intact Specimen Devices
      • 4.6.6 Biopsy Marker Clips
    • 4.7 Market Analysis (Including Drivers, Limiters, and Opportunities)
      • 4.7.1 Surgical Excision
      • 4.7.2 Fine Needle Aspiration
      • 4.7.3 Spring-Loaded Core Needle Biopsies
      • 4.7.4 Vacuum-Assisted Devices
      • 4.7.5 Large Volume / Intact Specimen Devices
      • 4.7.6 Marker Clips
    • 4.8 Summary and Conclusions
    • Exhibit 4.1: Core Needle Biopsy Devices
    • Exhibit 4.2: Large-Volume Contiguous Biopsy Devices
    • Exhibit 4.3: Diagnostic Accuracy of Stereotactic Biopsy Procedures
    • Exhibit 4.4: Relative Volumes of Biopsy Device Specimens
    • Exhibit 4.5: Medicare Reimbursement: Vacuum-Assisted Biopsy Methods
    • Exhibit 4.6: Medicare Reimbursement: Spring-Loaded Biopsy Methods
    • Exhibit 4.7: Stereotactic-Guided Biopsy: Vacuum Assisted Device: Example of Facility Profit
    • Exhibit 4.8: Excisional Biopsy Procedure Volume Forecast (2006-2012E)
    • Exhibit 4.9: Breast Biopsy Procedures, Historical (1990, 1994, 1998, 2002)
    • Exhibit 4.10: Breast Biopsy Procedure Volume Forecast (2006-2012E)
    • Exhibit 4.11: Breast Biopsy Market Procedure Volume Forecast (2006-2012E)
    • Exhibit 4.12: Spring-Loaded Biopsy Device Market Forecast (2006-2012E)
    • Exhibit 4.13: Spring-Loaded Biopsy Device Market, Share by Supplier (2006)
    • Exhibit 4.14: Vacuum-Assisted Biopsy Device Market Forecast, Disposables vs. Capital Equipment (2006-2012E)
    • Exhibit 4.15: Vacuum-Assisted Biopsy Device Market Forecast (2006-2012E)
    • Exhibit 4.16: Vacuum-Assisted Biopsy Device Market, Share by Supplier (2006)
    • Exhibit 4.17: Biopsy Marker Device Market Forecast (2006-2012E)
    • Exhibit 4.18: Biopsy Marker Device Market, Share by Supplier (2006)

    5. Breast Disease Therapies and Therapeutic Devices

    • 5.1 Excision
      • 5.1.1 Lumpectomy
      • 5.1.2 Mastectomy
      • 5.1.3 Lymphadectomies
        • 5.1.3.1 Sentinel Lymph Node Excision
    • 5.2 Radiation Therapy
      • 5.2.1 Breast Brachytherapy
    • 5.3 Ablation Therapies
    • 5.4 Market Analysis (Including Drivers, Limiters, and Opportunities)
      • 5.4.1 Excisional Devices
      • 5.4.2 Brachytherapy Devices
      • 5.4.3 Ablation Devices
    • 5.5 Summary and Conclusions
    • Exhibit 5.1: Therapeutic Methods: Breast Conservation Therapy
    • Exhibit 5.2: Therapeutic Methods: Mastectomy
    • Exhibit 5.3: Excision Procedure Volume Forecast (2006-2012E)
    • Exhibit 5.4: Mastectomy Procedures: Inpatient vs. Outpatient
    • Exhibit 5.5: Lumpectomy Procedure Volume Forecast (2006-2012E)
    • Exhibit 5.6: Lumpectomy Procedure Volumes, by Tumor size (2006-2012E)
    • Exhibit 5.7: Breast Brachytherapy Illustration
    • Exhibit 5.8: Breast Brachytherapy Market Forecast (2006-2012E)
    • Exhibit 5.9: Tumor Cryoablation Illustration

    6. Company Profiles

    • 6.1 Aurora Imaging
    • 6.2 CR Bard
    • 6.3 Cytyc
    • 6.4 FujiFilm
    • 6.5 General Electric
    • 6.6 Hologic
    • 6.7 Johnson & Johnson (Ethicon Endo-Surgery)
    • 6.8 Philips
    • 6.9 SenoRx
    • 6.10 Siemens
    • 6.11 Suros Surgical
    • 6.12 Toshiba

    U.S. BREAST DISEASE DIAGNOSIS AND THERAPY MARKETS published by Life Science Intelligence, Inc. in July 31, 2007. This report consists of 244 Pages / 98 Exhibits and the price starts from US $ 3900.

Back to Top